DEERFIELD MANAGEMENT COMPANY, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001009258

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q1 2026 · 78 positions · Total reported value $7.59B · Top-10 concentration 52.1% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 38.6% · 10 new · 12 cut · 12 exited

Active Share (vs S&P 500): 99.6% · vs QQQ: 99.9% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +17.1% · vs SPY +2.2% · Prev Value $7.59B — last quarter positions weighted by this quarter price moves · ranking

In its Q1 2026 13F filing, DEERFIELD MANAGEMENT COMPANY, L.P. disclosed 78 equity positions with a combined reported value of $7.59B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 52.1% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q1 2026 were NUVL ($1.77B), COGT ($348.10M), PRAX ($310.38M). By sector, the heaviest allocations are Health Care 71.9%, Industrials 0.8%. Versus the prior quarter, allocation shifted toward Health Care (+2.4pp) and away from Technology (-0.5pp), Consumer Discretionary (-0.6pp).

Versus the prior quarter, DEERFIELD MANAGEMENT COMPANY, L.P. opened 10 new positions, trimmed 12 and fully exited 12, a turnover rate of 38.6% of positions. The portfolio's overlap with the prior quarter was 44% of names.

The largest new positions opened in Q1 2026 were SNDX ($88.30M), DNTH ($85.58M), PFE ($85.36M).

Of the 12 positions fully exited versus the prior quarter, the largest were PHR ($33.82M), MRNA ($29.49M), VTR ($27.39M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q1 2026)

  • SNDX SYNDAX PHARMACEUTICALS INC · $88.30M
  • DNTH DIANTHUS THERAPEUTICS INC COM · $85.58M
  • PFE PFIZER INC · $85.36M
  • ZBIO ZENAS BIOPHARMA INC COM · $67.25M
  • GMAB GENMAB A/S · $66.06M
  • BMRN BIOMARIN PHARMACEUTICAL INC · $48.10M
  • TYRA TYRA BIOSCIENCES INC COM · $21.03M
  • DRUG BRIGHT MINDS BIOSCIENCES INC · $20.65M

Fully Exited (vs previous quarter)

  • PHR PHREESIA INC · prev qtr: $33.82M
  • MRNA MODERNA INC · prev qtr: $29.49M
  • VTR VENTAS INC · prev qtr: $27.39M
  • SYRE SPYRE THERAPEUTICS INC · prev qtr: $23.28M
  • EWTX EDGEWISE THERAPEUTICS INC · prev qtr: $19.00M
  • CRMD CORMEDIX INC · prev qtr: $12.89M
  • MDLN MEDLINE INC · prev qtr: $10.92M
  • OMDA OMADA HEALTH INC · prev qtr: $8.73M

Insider Transactions (Form 4)

Latest DEERFIELD MANAGEMENT COMPANY, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-07-15 D Nuvalent, Inc. 3,444 $124.00 SEC filing
2026-07-15 U Nuvalent, Inc. 5,146 $124.00 SEC filing
2026-07-15 D Nuvalent, Inc. 650,000 $124.00 SEC filing
2026-07-15 D Nuvalent, Inc. 8,299,225 $124.00 SEC filing
2026-06-16 Award Nuvalent, Inc. 3,444 — SEC filing
2026-06-11 Conversion Parabilis Medicines, Inc. 407,132 — SEC filing
2026-06-11 Conversion Parabilis Medicines, Inc. 260,992 — SEC filing
2026-06-11 Conversion Parabilis Medicines, Inc. 149,238 — SEC filing

All insider transactions →

Fund Profile

Deerfield Management Company, L.P. is a New York-based hedge fund founded by Marianne and James Chadwin, known for its quantitative and fundamental research approach focused primarily on healthcare and biotechnology investments.

Investment Approach

Combines quantitative analysis with fundamental research

Specializes in healthcare and biotechnology sectors

Utilizes both public and private investment strategies

Asset Classes & Strategy

Primarily focused on long/short equity positions

Specializes in healthcare and biotechnology investments

Also invests in other sectors with strong fundamental research

Key Personnel

Marianne Chadwin (Co-founder)

James Chadwin (Co-founder)

Team of experienced portfolio managers and researchers

AUM & Performance

Manages approximately $19.1 billion in assets under management

Performance data not publicly disclosed

All information is based on publicly available SEC filings and company disclosures.

Sector Allocation

Health Care 71.9%
Technology 0.6%
Materials 0.0%
Other 26.7%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 17.25M $1.77B 23.29%
23.29%
Hold
2 9.04M $348.10M 4.59%
4.59%
Hold
3 963.35K $310.38M 4.09%
4.09%
Add
4 20.21M $272.99M 3.60%
3.60%
Hold
5 457.00K $270.99M 3.57%
3.57%
Add
6 2.30M $223.38M 2.94%
2.94%
Reduce
7 70.00M $209.44M 2.76%
2.76%
Hold
8 1.71M $195.64M 2.58%
2.58%
Hold
9 5.92M $193.73M 2.55%
2.55%
Reduce
10 35.61M $160.23M 2.11%
2.11%
Add
11 11.64M $159.19M 2.10%
2.10%
Hold
12 3.72M $149.74M 1.97%
1.97%
Reduce
13 15.04M $143.16M 1.89%
1.89%
Add
14 2.70M $139.43M 1.84%
1.84%
Add
15 7.69M $139.07M 1.83%
1.83%
Add
16 11.48M $136.58M 1.80%
1.80%
Hold
17 4.26M $136.52M 1.80%
1.80%
Add
18 4.52M $105.72M 1.39%
1.39%
Hold
19 1.57M $98.65M 1.30%
1.30%
Reduce
20 3.94M $97.64M 1.29%
1.29%
Reduce
21 3.10M $94.42M 1.24%
1.24%
Reduce
22 1.62M $93.95M 1.24%
1.24%
Add
23 60.00M $90.61M 1.19%
1.19%
Hold
24 3.13M $88.31M 1.16%
1.16%
Hold
25 3.78M $88.30M 1.16%
1.16%
New
26 4.15M $86.75M 1.14%
1.14%
Add
27 61.00M $85.86M 1.13%
1.13%
Add
28 1.02M $85.58M 1.13%
1.13%
New
29 3.04M $85.36M 1.12%
1.12%
New
30 610.00K $80.36M 1.06%
1.06%
Reduce
31 3.72M $79.82M 1.05%
1.05%
Hold
32 13.57M $74.09M 0.98%
0.98%
Hold
33 65.00M $67.25M 0.89%
0.89%
New
34 4.75M $66.90M 0.88%
0.88%
Hold
35 72.69M $66.65M 0.88%
0.88%
Hold
36 2.46M $66.06M 0.87%
0.87%
New
37 226.07K $63.02M 0.83%
0.83%
Hold
38 828.00K $62.80M 0.83%
0.83%
Hold
39 7.50M $60.26M 0.79%
0.79%
Hold
40 1.82M $59.37M 0.78%
0.78%
Hold
41 2.21M $56.07M 0.74%
0.74%
Reduce
42 1.53M $50.98M 0.67%
0.67%
Reduce
43 304.01K $48.47M 0.64%
0.64%
Add
44 851.56K $48.10M 0.63%
0.63%
New
45 561.17K $46.74M 0.62%
0.62%
Hold
46 7.81M $44.51M 0.59%
0.59%
Hold
47 4.89M $43.72M 0.58%
0.58%
Hold
48 657.00K $42.01M 0.55%
0.55%
Add
49 34.28M $40.03M 0.53%
0.53%
Hold
50 970.59K $38.91M 0.51%
0.51%
Hold

FAQ

What did DEERFIELD MANAGEMENT COMPANY, L.P. buy in 2026-Q1?

In its 2026-Q1 13F filing, DEERFIELD MANAGEMENT COMPANY, L.P. reported 78 equity positions worth $7.59B in aggregate; its largest disclosed positions were NUVL ($1.77B), COGT ($348.10M), PRAX ($310.38M).

How large is DEERFIELD MANAGEMENT COMPANY, L.P.'s portfolio?

DEERFIELD MANAGEMENT COMPANY, L.P. reported $7.59B of long equity holdings across 78 positions as of 2026-Q1. Top-10 holdings account for 52.1% of reported value.

What is DEERFIELD MANAGEMENT COMPANY, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/deerfield-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →